



SurModics Introduces New StabilBlot(TM) Buffer at American Association for Clinical Chemistry - Clinical Lab Expo

July 27, 2010

EDEN PRAIRIE, Minn., Jul 27, 2010 (BUSINESS WIRE) --

SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, will introduce its StabilBlot(TM) Buffer (Protein-Free) product at the American Association for Clinical Chemistry (AACC) - Clinical Lab Expo, July 27-29, 2010 in Anaheim, CA (booth #3424).

StabilBlot buffer is the newest member of SurModics' Stabil(TM) family of quality, market-proven immunodiagnostic reagents. *StabilBlot* buffer was developed for blocking and antibody dilution in blotting applications. Data indicate that *StabilBlot* buffer significantly reduces background and increases signal in western blot applications. *StabilBlot* buffer is:

- Protein-free to minimize cross-reactivity
- An excellent blocking buffer that significantly reduces background
- Used for nitrocellulose and polyvinylidene fluoride (PVDF) membranes
- Strongly recommended as an antibody diluent
- Compatible with biotinylated antibodies

"This newest addition to SurModics' line of *Stabil* immunodiagnostic reagents demonstrates the flexibility of our capabilities to support the *in vitro* diagnostics industry," said Phil Ankeny, Interim CEO of SurModics. "SurModics remains committed to developing additional products based on this technology, enabling us to better serve our customers' needs."

To learn more about SurModics' *in vitro* diagnostics products, please visit with one of our representatives in booth 3424 at the AACC Clinical Lab Expo July 27-29, visit our website (www.surmodicsivd.com), or contact customer service at 952-829-2709 or orders@surmodics.com.

About SurModics, Inc.

SurModics' vision is to extend and improve the lives of patients through technology innovation. The Company partners with the world's foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved diagnosis and treatment for patients. Core offerings include: drug delivery technologies (coatings, microparticles, nanoparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for *in vitro* diagnostic test kits and specialized surfaces for cell culture and microarrays. SurModics is headquartered in Eden Prairie, Minnesota and its SurModics Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more information about the Company, visit www.surmodics.com. The content of SurModics' website is not part of this release or part of any filings the Company makes with the SEC.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations, such as those regarding the ability of our partners to commercialize products using our technologies, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including those identified under "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2009, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at www.surmodics.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events. Source: SurModics, Inc.

SOURCE: SurModics, Inc.

SurModics, Inc.
Phil Ankeny, Interim CEO, Senior VP and CFO
(952) 829-2700